Natural killer cell

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells

Retrieved on: 
Tuesday, July 13, 2021
Medical specialties, Branches of biology, Clinical medicine, Immune system, Immunology, T cell, Cytotoxicity, Immunotherapy, Natural killer cell, Cancer immunotherapy

The publication, titled BTN2A1, An Immune-checkpoint Targeting V9V2 T Cell Cytotoxicity Against Malignant C ells summarizes the findings of the interaction between specific BTN subtypes that efficiently activate V9V2 T cells, an important subset of cytotoxic T cells.

Key Points: 
  • The publication, titled BTN2A1, An Immune-checkpoint Targeting V9V2 T Cell Cytotoxicity Against Malignant C ells summarizes the findings of the interaction between specific BTN subtypes that efficiently activate V9V2 T cells, an important subset of cytotoxic T cells.
  • In addition, the publication demonstrates that an anti-BTN2A1-specific antibody is able to inhibit the cytotoxic function of the V9V2 T cells.
  • BTNs represent a new super-family of immunoregulators present on the surface of several cell types, including cancer cells.
  • These findings advance the understanding of how BTNs activate V9V2 T cell function against tumor cells.

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

Retrieved on: 
Monday, July 12, 2021
Branches of biology, Biology, Medical specialties, Stem cells, Biotechnology, Immune system, Lymphocytes, Natural killer cell, Hematopoietic stem cell, Myelodysplastic syndrome, Clonal hypereosinophilia

MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.

Key Points: 
  • MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells and the level of dysfunction is predictive of overall survival.
  • Current treatments, including chemotherapy and bone marrow/stem cell transplantation, have varying degrees of success, and there is no known cure for MDS.
  • In the lab we have shown that INKmune binds to multiple NK receptors and initiates the activation of over 3000 genes associated with function, trafficking, proliferation and survival.
  • No single cytokine in our hands has such broad, physiological effects, which has inspired us to refer to INKmune as a pseudokine.

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

Retrieved on: 
Tuesday, July 6, 2021
Life sciences, Immune system, Medical specialties, Branches of biology, Bristol-Myers Squibb, Bristol Myers Squibb, Agenus, Cancer immunotherapy, Monoclonal antibodies, Natural killer cell, Squib, Compugen

AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.

Key Points: 
  • AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity.
  • Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer.
  • Under the terms of the agreement with Bristol Myers Squibb, Agenus receives a $200 million upfront payment in connection with the closing.
  • Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide.

Exacis Biotherapeutics Makes Strategic Investment In Manufacturing by Hiring Head of Technical Operations and Securing Space in a GMP Cleanroom Facility Recently Completed by Factor Bioscience

Retrieved on: 
Thursday, July 1, 2021
Immune system, Branches of biology, Clinical medicine, Medical specialties, Lymphocytes, Natural killer cell, Chimeric antigen receptor T cell, Cleanroom

Exacisis partnering with parent Factor Bioscience toproduce its iPSC-derived CAR-T and NK cells within a GMP cleanroomfacilitybuilt by Factor,and Exacis has hiredBryan Jones PhD as its Head of Technical Operations.

Key Points: 
  • Exacisis partnering with parent Factor Bioscience toproduce its iPSC-derived CAR-T and NK cells within a GMP cleanroomfacilitybuilt by Factor,and Exacis has hiredBryan Jones PhD as its Head of Technical Operations.
  • Exacis' parent company, Factor Bioscience, recently completed construction of a 5,000 square foot GMP cleanroom facility at its Cambridge, Massachusetts headquarters.
  • Exacis will use this new facility to produce its allogeneic mRNA engineered cell-therapy product candidates for non-clinical and clinical testing.
  • Dr. Jones will oversee the buildout of the Manufacturing and Quality Operations working alongside Factor Bioscience in the new facility.

Alphageneron to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th, 2021

Retrieved on: 
Saturday, June 26, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Induced stem cells, Immune system, Natural killer cell, Induced pluripotent stem cell, Cell therapy, IPSCS

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.

Key Points: 
  • CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneronor theCompany), a privately-held clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer (NK) cellular and antibody therapeutics announced that Robert Brooks, JD, founder and Chief Executive Officer of Alphageneron, will participate in the ROTH Healthcare Private Company Forum to be hosted virtually on Monday, June 28, 2021.
  • Alphageneron is also planning a Phase I clinical Combination trial with Metastatic Colorectal cancer withallogeneic donor genetically edited NK cell therapy, (ANKASTIM) in the United States.
  • To register for this virtual event click www.roth.com/healthcareprivateday or please contact Gerald Roger, c/o Trinity Capital Advisers Tel.
  • Alphageneron is also developing allogeneic Induced pluripotent stem cells (iPSCs) CAR-engineered NK (CAR NK) cells to an undisclosed target.

Bio-Techne and Catamaran Bio Announce Expanded Collaboration for CAR-NK Cell Manufacturing Technologies

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Immune system, Stem cells, Cell biology, Lymphocytes, Natural killer cell, Cell therapy, Bio-Techne

MINNEAPOLIS and CAMBRIDGE, Mass., June 24, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Catamaran Bio today announced an expansion of their collaboration for the development of cell engineering and cell process technologies for use by Catamaran in the manufacturing of CAR-NK cell therapy products.

Key Points: 
  • MINNEAPOLIS and CAMBRIDGE, Mass., June 24, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Catamaran Bio today announced an expansion of their collaboration for the development of cell engineering and cell process technologies for use by Catamaran in the manufacturing of CAR-NK cell therapy products.
  • The companies have now broadened the scope of their collaboration to include the development of novel cell expansion technologies for use in the manufacturing of CAR-NK cell therapy products.
  • "We have established a successful track record of collaborating with Bio-Techne to optimize technologies for use in CAR-NK cell engineering and manufacturing.
  • Through the collaboration, the Catamaran and Bio-Techne teams are focused on developing and enhancing technologies for scalable and robust manufacturing of allogeneic CAR-NK cell therapies.

Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR‑NK Cell Manufacturing Technologies

Retrieved on: 
Thursday, June 24, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Biology, Life sciences, Biotechnology, Immune system, Stem cells, Cell biology, Bio-Techne, Natural killer cell, Cell therapy

Catamaran Bio and Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of their collaboration for the development of cell engineering and cell process technologies for use by Catamaran in the manufacturing of CAR-NK cell therapy products.

Key Points: 
  • Catamaran Bio and Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of their collaboration for the development of cell engineering and cell process technologies for use by Catamaran in the manufacturing of CAR-NK cell therapy products.
  • The companies have now broadened the scope of their collaboration to include the development of novel cell expansion technologies for use in the manufacturing of CARNK cell therapy products.
  • We have established a successful track record of collaborating with Bio-Techne to optimize technologies for use in CAR-NK cell engineering and manufacturing.
  • Through the collaboration, the Catamaran and Bio-Techne teams are focused on developing and enhancing technologies for scalable and robust manufacturing of allogeneic CAR-NK cell therapies.

Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Life sciences, Biology, Immune system, Cancer immunotherapy, Stem cells, Lymphocytes, Biotechnology, Induced pluripotent stem cell, Chimeric antigen receptor T cell, Natural killer cell, IPSCS

and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Olivier Goudard, PharmD, MBA has been appointed as Chief Operating Officer, effective immediately.

Key Points: 
  • and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Olivier Goudard, PharmD, MBA has been appointed as Chief Operating Officer, effective immediately.
  • Dr. Goudard will lead cross-functional integration of external and internal R&D, manufacturing, regulatory affairs, and clinical development.
  • Were delighted to welcome Olivier to Cytovias leadership team, added Dr. Daniel Teper, CEO of Cytovia Therapeutics.
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.

Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference

Retrieved on: 
Monday, June 21, 2021
Branches of biology, Medical specialties, Immune system, Immunology, Lymphocytes, Natural killer cell, Cancer immunotherapy

A live webcast of the event will be available by visiting the "Presentations" page in the Investors section of GT Biopharma's website at www.gtbiopharma.com/news-media/presentations .

Key Points: 
  • A live webcast of the event will be available by visiting the "Presentations" page in the Investors section of GT Biopharma's website at www.gtbiopharma.com/news-media/presentations .
  • GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE NK cell engager platform.
  • Our TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells (NK cells).
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Kytopen Awarded NIH Grant of Up to $2M to Unlock the Power of Engineered Natural Killer (NK) Cells via Flowfect® Platform

Retrieved on: 
Wednesday, June 16, 2021
Engineering, Health, Manufacturing, Genetics, Pharmaceutical, Biotechnology, Life sciences, Branches of biology, Immune system, Biology, Lymphocytes, Natural killer cell, Biotechnology, Biological engineering, Pharmacy, the Flowfect® Technology, Kytopen, THE FLOWFECT® TECHNOLOGY, KYTOPEN

Schematic depictions of the core Flowfect technology (center) and our two implementations of the high-throughput Flowfect Array (left) for automated discovery and Flowfect Tx (right) for clinical manufacturing.

Key Points: 
  • Schematic depictions of the core Flowfect technology (center) and our two implementations of the high-throughput Flowfect Array (left) for automated discovery and Flowfect Tx (right) for clinical manufacturing.
  • Dr. Garcia explains that engineered NK cells have tremendous therapeutic promise including the potential to treat solid tumors in an allogeneic modality.
  • The Flowfect platform will facilitate high-throughput target discovery while providing a clear path towards clinical manufacturing of next-generation cell products.
  • The current research proposes to engineer non-activated NK cells with Cas RNPs for gene editing using the Flowfect platform.